Como se calcula la biodisponibilidad absoluta?

F = (AUCno-IV x DoseIV) / (AUCIV x Doseno-IV). Se compara el AUC despues de administracion no-IV (ej. SC) con el AUC despues de administracion IV en el mismo sujeto. Expresado como fraccion o porcentaje.

Por que la biodisponibilidad oral de peptidos es tan baja?

Tres barreras principales: degradacion por enzimas GI (pepsina, tripsina, peptidasas), pH extremo del estomago, y baja permeabilidad a traves del epitelio intestinal (tight junctions excluyen moleculas grandes). Resulta en BA menor a 1% tipicamente.

Que factores afectan la absorcion SC?

Peso molecular (mayor = mas linfatico), hidrofilicidad, concentracion, volumen inyectado, sitio de inyeccion (abdomen, muslo, brazo), flujo sanguineo local, grosor del tejido adiposo, y degradacion por peptidasas tisulares.

Cuando usar IM vs SC para peptidos?

SC es preferido para auto-administracion y tratamiento cronico (menos dolor, mas facil). IM se usa para depot formulations, volumenes mayores, o cuando se necesita absorcion mas rapida. Ambos tienen BA alta (50-100%).

Estudios de Biodisponibilidad de Peptidos

Categorías: Metodología de Investigación, Información General

La biodisponibilidad determina cuanto peptido alcanza la circulacion sistemica. Es critica para entender eficacia y optimizar formulaciones.

Resumen Simplificado

Biodisponibilidad se evalua comparando AUC de ruta no-IV vs IV; SC tipicamente 50-100%, oral menor 1%.

Conceptos de biodisponibilidad

Biodisponibilidad es fraccion absorbida. Definition. Fraction of dose reaching systemic circulation. Unchanged form. Active moiety. Absolute bioavailability. F = AUCroute / AUCiv. Relative bioavailability. Comparison between formulations. Factors affecting BA. Route of administration. Formulation. Physicochemical properties. Size. Charge. Lipophilicity. First-pass metabolism. Precio-systemic elimination. Enzymatic degradation. GI tract. Liver. Injection site. Peptide-specific factors. Molecular weight. Larger = slower absorption. Sequence. Cleavage sites. Aggregation state. Physical form. Formulation factors. Excipients. pH. Concentration. Volume. BA determina dose. Low BA requires higher doses. Safety implications. Cost implications.

Biodisponibilidad oral

Oral BA es muy baja para peptidos. Typical range. Less than 1%. Often less than 0.1%. Barriers. Enzymatic degradation. Stomach. Pepsin. Acidic pH. Small intestine. Trypsin. Chymotrypsin. Peptidases. Brush border enzymes. Luminal degradation. Membrane permeability. Tight junctions. Limited paracellular. Transcellular negligible. Size exclusion. P-glycoprotein efflux. First-pass hepatic. CYP enzymes. Peptidases. Strategies to improve. Enzyme inhibitors. Aprotinin. Soybean trypsin inhibitor. Permeation enhancers. SNAC. Sodium N-[8-(2-hydroxybenzoyl)amino]caprylate. Formulation. Enteric coating. Nanoparticles. Liposomes. Chemical modification. PEGylation. Cyclization. D-amino acids. Oral delivery remains challenge. Research continues. Few peptides orally available. Semaglutide. Cyclosporine. Success stories but limited.

Biodisponibilidad subcutanea

SC es ruta principal para peptidos. Typical BA. 50-100%. Often 70-90%. Variability. Inter-subject. Intra-subject. Injection site. Abdomen. Thigh. Arm. Different rates. Absorption mechanisms. Capillaries. Primary route. Blood flow dependent. Lymphatics. Important for larger peptides. Greater than 16 kDa. Factors affecting SC BA. Molecular weight. Smaller faster. Larger more lymphatic. Hydrophilicity. Charge. Formulation. Concentration. Volume. 1-2 mL typical. Injection technique. Needle length. Angle. Depth. Tissue characteristics. Adipose thickness. Blood flow. Local degradation. Tissue peptidases. Injection site reactions. Pain. Bruising. Nodules. SC absorption is favorable. Non-invasive compared to IV. Patient self-administration possible. SC is standard for peptide therapeutics.

Biodisponibilidad intramuscular

IM administration alternative. BA generally high. 80-100%. Often complete absorption. Absorption. Faster than SC. Blood flow higher. Muscle tissue. Vascularized. Larger volumes possible. 2-5 mL. Injection sites. Deltoid. Gluteus. Vastus lateralis. Site differences. Absorption rate varies. Deltoid fastest. Gluteus slowest. Factors. Blood flow. Muscle mass. Activity level. Injection technique. Needle length. 1-2 inches. Z-track technique. Formulation considerations. Viscosity. Solubility. Depot formulations. Slow release. Oily vehicles. Microspheres. IM advantages. Rapid absorption. Larger volumes. Depot options. IM disadvantages. Pain. Muscle damage. Nerve injury risk. Sterile abscess. IM use cases. Emergency medications. Depot formulations. Vaccines. Less common for peptides than SC.

Metodos de evaluacion de BA

BA studies are systematic. Study design. Crossover preferred. Same subjects. Reduce variability. Randomization. Sequence assignment. Washout period. 5+ half-lives. Minimum to avoid carryover. Single dose. Standard approach. Multiple dose. If accumulation concerns. Reference. IV administration. 100% BA. Absolute BA calculation. Test route. Non-IV formulation. Dose adjustment. May differ from clinical dose. Sampling schedule. Pre-dose. Frequent early. Extended late. Full profile capture. PK parameters. AUC0-t. AUC0-infinity. Cmax. Tmax. t1/2. Bioanalytical method. Validated. LC-MS/MS. ELISA. Adequate sensitivity. LLOQ. Statistical analysis. Geometric mean ratio. 90% CI. Non-compartmental analysis. Population approach if sparse sampling. BA studies inform dosing. Route selection. Formulation optimization.

Factores que afectan biodisponibilidad

Multiple factors interact. Physicochemical properties. Molecular weight. Charge at physiological pH. Hydrophobicity. Solubility. Aggregation tendency. Sequence-specific. Peptide bond stability. Enzyme cleavage sites. Proline-rich sequences. Disulfide bridges. Formulation factors. Concentration. Higher = aggregation risk. pH. Stability vs absorption. Buffer. Ionic strength. Excipients. Surfactants. Stabilizers. Preservatives. Container closure. Adsorption risk. Siliconization. Patient factors. Body composition. Fat vs muscle. Blood flow. Activity level. Disease states. Renal impairment. Hepatic impairment. Genetic factors. Enzyme polymorphisms. Drug interactions. Concomitant medications. Food effects. Oral administration. Timing relative to meals. Understanding factors enables optimization. Predictable exposure. Consistent efficacy.

Hallazgos Clave

Biodisponibilidad absoluta = AUCruta / AUCIV; relativa compara formulaciones
Oral BA tipicamente menor a 1% por degradacion enzimatica y baja permeabilidad
SC BA tipicamente 50-100%; absorcion via capilares y linfaticos
IM BA generalmente 80-100% con absorcion mas rapida que SC
Estudios BA usan diseno crossover con washout de 5+ half-lives
Factores incluyen peso molecular, carga, formulacion, sitio inyeccion, estado paciente

Más artículos en Metodología de Investigación

Más artículos en Información General

Términos del glosario

Preguntas frecuentes

Como se calcula la biodisponibilidad absoluta?: F = (AUCno-IV x DoseIV) / (AUCIV x Doseno-IV). Se compara el AUC despues de administracion no-IV (ej. SC) con el AUC despues de administracion IV en el mismo sujeto. Expresado como fraccion o porcentaje.
Por que la biodisponibilidad oral de peptidos es tan baja?: Tres barreras principales: degradacion por enzimas GI (pepsina, tripsina, peptidasas), pH extremo del estomago, y baja permeabilidad a traves del epitelio intestinal (tight junctions excluyen moleculas grandes). Resulta en BA menor a 1% tipicamente.
Que factores afectan la absorcion SC?: Peso molecular (mayor = mas linfatico), hidrofilicidad, concentracion, volumen inyectado, sitio de inyeccion (abdomen, muslo, brazo), flujo sanguineo local, grosor del tejido adiposo, y degradacion por peptidasas tisulares.
Cuando usar IM vs SC para peptidos?: SC es preferido para auto-administracion y tratamiento cronico (menos dolor, mas facil). IM se usa para depot formulations, volumenes mayores, o cuando se necesita absorcion mas rapida. Ambos tienen BA alta (50-100%).

Volver a la biblioteca de investigación